Paul Tudor Jones’s BSX Holdings & Trades

First Buy
Q3 2013
Duration Held
49 Quarters
Largest Add
Q2 2015
+629,446 Shares
Current Position
660,186 Shares
$64.45 M Value

Paul Tudor Jones's BSX Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 660,186 shares of Boston Scientific Corporation (BSX) worth $64.45 M, representing 0.11% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.

Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in BSX, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2015, adding 629,446 shares. Largest reduction occurred in Q2 2016, reducing 616,006 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Boston Scientific Corporation (BSX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Boston Scientific Corporation (BSX) Trades by Paul Tudor Jones

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2013 +13,100 New Buy 13,100 $11.76
Q4 2013 -13,100 Sold Out 13,100 $0.00
Q1 2014 +17,944 New Buy 17,944 $13.54
Q2 2014 +9,096 Add 50.69% 27,040 $12.76
Q3 2014 +62,301 Add 230.40% 89,341 $11.81
Q4 2014 +73,160 Add 81.89% 162,501 $13.25
Q1 2015 -141,947 Reduce 87.35% 20,554 $17.76
Q2 2015 +629,446 Add 3062.40% 650,000 $17.70
Q3 2015 -650,000 Sold Out 650,000 $0.00
Q2 2016 +33,994 New Buy 33,994 $23.36
Q3 2016 -7,384 Reduce 21.72% 26,610 $23.79
Q4 2016 -26,610 Sold Out 26,610 $0.00
Q4 2017 +195,667 New Buy 195,667 $24.79
Q1 2018 -168,980 Reduce 86.36% 26,687 $27.32
Q2 2018 +3,936 Add 14.75% 30,623 $32.69
Q3 2018 -30,623 Sold Out 30,623 $0.00
Q1 2019 +61,225 New Buy 61,225 $38.38
Q2 2019 -61,225 Sold Out 61,225 $0.00
Q1 2020 +46,362 New Buy 46,362 $32.63
Q2 2020 -13,462 Reduce 29.04% 32,900 $35.11
Q3 2020 +48,401 Add 147.12% 81,301 $38.22
Q4 2020 -69,180 Reduce 85.09% 12,121 $35.97
Q1 2021 +9,103 Add 75.10% 21,224 $38.64
Q2 2021 -21,224 Sold Out 21,224 $0.00
Q3 2021 +10,200 New Buy 10,200 $43.43
Q4 2021 +6,556 Add 64.27% 16,756 $42.49
Q1 2022 +11,417 Add 68.14% 28,173 $44.30
Q2 2022 -28,173 Sold Out 28,173 $0.00
Q1 2023 +218,602 New Buy 218,602 $0.05
Q2 2023 +17,634 Add 8.07% 236,236 $54.09
Q3 2023 +72,449 Add 30.67% 308,685 $52.80
Q4 2023 -104,697 Reduce 33.92% 203,988 $57.81
Q1 2024 -47,279 Reduce 23.18% 156,709 $68.49
Q2 2024 -142,175 Reduce 90.73% 14,534 $77.01
Q3 2024 +315,270 Add 2169.19% 329,804 $83.80
Q4 2024 -329,804 Sold Out 329,804 $0.00
Q1 2025 +256,131 New Buy 256,131 $100.88
Q2 2025 +394,489 Add 154.02% 650,620 $107.41
Q3 2025 +9,566 Add 1.47% 660,186 $97.63

Paul Tudor Jones's Boston Scientific Corporation Investment FAQs

Paul Tudor Jones first purchased Boston Scientific Corporation (BSX) in Q3 2013, acquiring 13,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Boston Scientific Corporation (BSX) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's largest addition to Boston Scientific Corporation (BSX) was in Q2 2015, adding 650,000 shares worth $11.5 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 660,186 shares of Boston Scientific Corporation (BSX), valued at approximately $64.45 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Boston Scientific Corporation (BSX) represents approximately 0.11% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's peak holding in Boston Scientific Corporation (BSX) was 660,186 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.